Aaron G.l. Fletcher - 13 Jun 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Reporting relationship: 10%+ Owner
Issuer ticker: LTRN
Reported as of: 13 Jun 2025
Net transaction value: -$123,600
SEC form: 4
Accepted by SEC: 13 Jun 2025, 19:57:00 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: Aaron G.L. Fletcher By: /s/ John Fucci, as attorney-in-fact

Key filing fact

Aaron G.l. Fletcher filed Form 4 for Lantern Pharma Inc. (LTRN) on 13 Jun 2025.

Key facts

This page summarizes Aaron G.l. Fletcher's Form 4 filing for Lantern Pharma Inc. (LTRN).
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jun 2025, 19:57.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: -$123,600.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001789490 Primary reporting owner

Fletcher Aaron G.L.

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Aaron G.L. Fletcher By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001697316

BIOS Fund I, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001700297

BIOS Fund I QP, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001714576

BIOS Fund II, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001716869

BIOS Fund II QP, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001728851

BIOS Fund II NT, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II NT, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001813314

Bios Equity Partners, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Equity Partners, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001813313

Bios Equity Partners II, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Equity Partners II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001813845

BIOS Capital Management, LP

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Capital Management, LP By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

CIK 0001813844

BIOS Advisors GP, LLC

Relationship: 10%+ Owner
Address: C/O BIOS PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Advisors GP, LLC By: /s/ John Fucci, as attorney-in-fact
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LTRN transaction

Common Stock

Sale

Transaction value: $22,267
Shares: -7,206
Change %: -3.7%
Price: $3.09
Shares after: 189,117
Date: 13 Jun 2025
Ownership: By Bios Fund I QP, LP
Footnotes: F1, F2, F3, F4

LTRN transaction

Common Stock

Sale

Transaction value: $38,066
Shares: -12,319
Change %: -3.7%
Price: $3.09
Shares after: 323,335
Date: 13 Jun 2025
Ownership: By Bios Fund I, LP
Footnotes: F1, F2, F3, F4

LTRN transaction

Common Stock

Sale

Transaction value: $5,880
Shares: -1,903
Change %: -3.7%
Price: $3.09
Shares after: 49,957
Date: 13 Jun 2025
Ownership: By Bios Fund II NT, LP
Footnotes: F1, F2, F3, F4

LTRN transaction

Common Stock

Sale

Transaction value: $43,934
Shares: -14,218
Change %: -3.7%
Price: $3.09
Shares after: 373,178
Date: 13 Jun 2025
Ownership: By Bios Fund II QP, LP
Footnotes: F1, F2, F3, F4

LTRN transaction

Common Stock

Sale

Transaction value: $13,454
Shares: -4,354
Change %: -3.7%
Price: $3.09
Shares after: 114,272
Date: 13 Jun 2025
Ownership: by Bios Fund II, LP
Footnotes: F1, F2, F3, F4

LTRN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 26,093
Date: 13 Jun 2025
Ownership: By BP Directors, LP
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Aaron G.l. Fletcher is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F2

Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.

Footnote F3

Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

Footnote F4

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Leslie W. Kreis as the designated filer.